DiaKine Therapeutics, Inc. to Be Awarded Patent for Restoring Insulin Producing Cell Function in Diabetics

Published: Apr 01, 2008

CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--DiaKine Therapeutics, Inc. today announced that the U.S. Patent and Trademark Office indicated its intent to grant a patent for the use of Lisofylline (LSF) to restore insulin-producing beta cell mass and function in people with diabetes. The patent application, entitled Pharmaceutical compositions and methods for restoring beta-cell mass and function, also covers the use of LSF in combination with a growth factor.

Back to news